drugset
drugset / Trial / NCT04951882

Application of hUC-MSCs in Treating Acute Lung Injury: a Single Center Prospective Clinical Research

NCT04951882 ↗

Phase 0 Unknown 30 enrolled Second Affiliated Hospital, School of Medicine, Zhejiang University
RandomizedParallel-groupOpen-labelTreatment

Summary

The patients suffered from acute lung ininjury (200\<PaO2/FiO2 ≤ 300) will be divided into two groups: MSCs-treated group: patients are treated by intravenous injection of hUC-MSCs suspention ; control group: patients were treated with vehicle(Albumin) . The standard Therapies of acute lung injury were the same in both groups. In the following-up days, all the patients were monitored by the same items to evaluate the therapeutic effects.

Timeline

Start
2021-06-09
Primary completion
2022-12-31
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator human derived umbilical cord derived mesenchymal stem cells Cell therapy — Intravenous

Indications

acute lung injury